KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

Oncologist · 2026-Jun-06 · PMID 42179186

Panel C提取完成待 EXE 对齐验证

time to first ≥50% reduction in MFSAF TSS

Figure 3. Change in MFSAF TSSs from baseline and likelihood of achieving a ≥50% reduction from baseline in MFSAF TSS in patients with myelofibrosis. (A) Percentage change in MFSAF TSS from baseline to week 24 (individual patient data; n = 117). Dotted line represents a 50% decrease in MFSAF TSS from baseline. (B) Median percentage change in MFSAF TSS from baseline. (C) Kaplan-Meier estimates of time to first ≥50% reduction in MFSAF TSS from baseline. Hashtags indicate patients with >100% percent change in MFSAF TSS from baseline. Tick marks indicate censored data. MFSAF, Myelofibrosis Symptom Assessment Form; TSS, total symptom score.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.58
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T17:51:55+00:00